Vyome Holdings, Inc. (HIND) Research

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

Market snapshot

Symbol
HIND
Price
$2.17
Day change
-0.46%
Market cap
$12.2M
P/E ratio
-0.97x
52-week range
1.75-18.6
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$15.00

Peer companies

  • Armata Pharmaceuticals, Inc. (ARMP)
  • C4 Therapeutics, Inc. (CCCC)
  • Codexis, Inc. (CDXS)
  • Compugen Ltd. (CGEN)
  • Insight Molecular Diagnostics Inc. (IMDX)
  • Innate Pharma S.A. (IPHA)
  • Nuvectis Pharma, Inc. (NVCT)
  • OmniAb, Inc. (OABI)

Recent insider activity

  • Pomichter Stanley D III — A-Award (17833 shares) on 2025-11-13
  • Pomichter Stanley D III — trade (0 shares) on 2025-08-15
  • Jolly Mohanjit — A-Award (454456 shares) on 2025-08-15
  • Jolly Mohanjit — trade (0 shares) on 2025-08-15
  • Tincoff John M. III — A-Award (17833 shares) on 2025-11-13

Open Vyome Holdings, Inc. (HIND) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.